{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:42:14Z","timestamp":1791362534235,"version":"4.3.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Adoptive transfer of engineered immune cells is a promising strategy for cancer treatment. However, low transduction efficiency particularly when large payload lentiviral vectors are used on primary T cells is a limitation for the development of cell therapy platforms that include multiple constructs bearing long DNA sequences. RB-340-1 is a new CAR T cell that combines two strategies in one product through a CRISPR interference (CRISPRi) circuit. Because multiple regulatory components are included in the circuit, RB-340-1 production needs delivery of two lentiviral vectors into human primary T cells, both containing long DNA sequences. To improve lentiviral transduction efficiency, we looked for inhibitors of receptors involved in antiviral response. BX795 is a pharmacological inhibitor of the TBK1\/IKK\u025b complex, which has been reported to augment lentiviral transduction of human NK cells and some cell lines, but it has not been tested with human primary T cells. The purpose of this study was to test if BX795 treatment promotes large payload RB-340-1 lentiviral transduction of human primary T cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To make the detection of gene delivery more convenient, we constructed another set of RB-340-1 constructs containing fluorescent labels named RB-340-1F. We incorporated BX795 treatment into the human primary T cell transduction procedure that was optimized for RB-340-1F. We tested BX795 with T cells collected from multiple donors, and detected the effect of BX795 on T cell transduction, phenotype, cell growth and cell function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found that BX795 promotes RB-340-1F lentiviral transduction of human primary T cells, without dramatic change in cell growth and T cell functions. Meanwhile, BX795 treatment increased CD8+ T cell ratios in transduced T cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These results indicate that BX795 treatment is effective, and might be a safe approach to promote RB-340-1F lentiviral transduction of human primary T cells. This approach might also be helpful for other T cell therapy products that need delivery of complicated platform via large payload lentiviral vectors.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12967-020-02526-2","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T11:03:39Z","timestamp":1600859019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Lentiviral delivery of combinatorial CAR\/CRISPRi circuit into human primary T cells is enhanced by TBK1\/IKK\u025b complex inhibitor BX795"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6788-8620","authenticated-orcid":false,"given":"Lingyu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghui","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Pelayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Denson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angshumala","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rona","family":"Harari-Steinfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei Stanley","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco M.","family":"Marincola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"issue":"1","key":"2526_CR1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-018-0355-5","volume":"6","author":"T Turan","year":"2018","unstructured":"Turan T, Kannan D, Patel M, Matthew Barnes J, Tanlimco SG, Lu R, et al. Immune oncology, immune responsiveness and the theory of everything. J Immunother Cancer. 2018;6(1):50.","journal-title":"J Immunother Cancer."},{"issue":"1","key":"2526_CR2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s40425-019-0602-4","volume":"7","author":"D Bedognetti","year":"2019","unstructured":"Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, et al. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer. 2019;7(1):131.","journal-title":"J Immunother Cancer."},{"issue":"12","key":"2526_CR3","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282\u201395.","journal-title":"Cancer Discov"},{"issue":"10","key":"2526_CR4","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504\u20136.","journal-title":"Nat Med"},{"issue":"4","key":"2526_CR5","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1158\/0008-5472.CAN-11-2637","volume":"72","author":"J Fourcade","year":"2012","unstructured":"Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 2012;72(4):887\u201396.","journal-title":"Cancer Res"},{"issue":"1","key":"2526_CR6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-019-0746-1","volume":"12","author":"H Wang","year":"2019","unstructured":"Wang H, Kaur G, Sankin AI, Chen F, Guan F, Zang X. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. J Hematol Oncol. 2019;12(1):59.","journal-title":"J Hematol Oncol."},{"issue":"7","key":"2526_CR7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.molmed.2012.04.009","volume":"18","author":"DE Gilham","year":"2012","unstructured":"Gilham DE, Debets R, Pule M, Hawkins RE, Abken H. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med. 2012;18(7):377\u201384.","journal-title":"Trends Mol Med."},{"issue":"9","key":"2526_CR8","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847\u201356.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2526_CR9","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA, et al. CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7(1):737.","journal-title":"Sci Rep."},{"issue":"3","key":"2526_CR10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-018-2281-2","volume":"68","author":"W Hu","year":"2019","unstructured":"Hu W, Zi Z, Jin Y, Li G, Shao K, Cai Q, et al. CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions. Cancer Immunol Immunother. 2019;68(3):365\u201377.","journal-title":"Cancer Immunol Immunother"},{"key":"2526_CR11","doi-asserted-by":"crossref","first-page":"6481","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367:6481.","journal-title":"Science."},{"issue":"4","key":"2526_CR12","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"KT Roybal","year":"2016","unstructured":"Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell. 2016;164(4):770\u20139.","journal-title":"Cell"},{"issue":"3","key":"2526_CR13","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.cell.2014.09.029","volume":"159","author":"LA Gilbert","year":"2014","unstructured":"Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell. 2014;159(3):647\u201361.","journal-title":"Cell"},{"issue":"2","key":"2526_CR14","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","volume":"154","author":"LA Gilbert","year":"2013","unstructured":"Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013;154(2):442\u201351.","journal-title":"Cell"},{"issue":"5","key":"2526_CR15","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","volume":"152","author":"LS Qi","year":"2013","unstructured":"Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013;152(5):1173\u201383.","journal-title":"Cell"},{"issue":"10","key":"2526_CR16","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","volume":"89","author":"P Carter","year":"1992","unstructured":"Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992;89(10):4285\u20139.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2526_CR17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jim.2019.06.015","volume":"472","author":"B Simon","year":"2019","unstructured":"Simon B, Harrer DC, Thirion C, Schuler-Thurner B, Schuler G, Uslu U. Enhancing lentiviral transduction to generate melanoma-specific human T cells for cancer immunotherapy. J Immunol Methods. 2019;472:55\u201364.","journal-title":"J Immunol Methods"},{"key":"2526_CR18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1472-6750-13-98","volume":"13","author":"AP Cribbs","year":"2013","unstructured":"Cribbs AP, Kennedy A, Gregory B, Brennan FM. Simplified production and concentration of lentiviral vectors to achieve high transduction in primary human T cells. BMC Biotechnol. 2013;13:98.","journal-title":"BMC Biotechnol"},{"key":"2526_CR19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-1-59745-409-4_8","volume":"506","author":"E Verhoeyen","year":"2009","unstructured":"Verhoeyen E, Costa C, Cosset FL. Lentiviral vector gene transfer into human T cells. Methods Mol Biol. 2009;506:97\u2013114.","journal-title":"Methods Mol Biol"},{"issue":"13","key":"2526_CR20","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/sj.gt.3301711","volume":"9","author":"R Schroers","year":"2002","unstructured":"Schroers R, Davis CM, Wagner HJ, Chen SY. Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection. Gene Ther. 2002;9(13):889\u201397.","journal-title":"Gene Ther"},{"issue":"5259","key":"2526_CR21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","volume":"272","author":"L Naldini","year":"1996","unstructured":"Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272(5259):263\u20137.","journal-title":"Science"},{"issue":"12","key":"2526_CR22","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1084\/jem.20040520","volume":"199","author":"H Hemmi","year":"2004","unstructured":"Hemmi H, Takeuchi O, Sato S, Yamamoto M, Kaisho T, Sanjo H, et al. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med. 2004;199(12):1641\u201350.","journal-title":"J Exp Med"},{"issue":"12","key":"2526_CR23","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1084\/jem.20040528","volume":"199","author":"AK Perry","year":"2004","unstructured":"Perry AK, Chow EK, Goodnough JB, Yeh WC, Cheng G. Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection. J Exp Med. 2004;199(12):1651\u20138.","journal-title":"J Exp Med"},{"issue":"2","key":"2526_CR24","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1074\/jbc.M805905200","volume":"284","author":"D Verpooten","year":"2009","unstructured":"Verpooten D, Ma Y, Hou S, Yan Z, He B. Control of TANK-binding kinase 1-mediated signaling by the gamma(1)34.5 protein of herpes simplex virus 1. J Biol Chem. 2009;284(2):1097\u2013105.","journal-title":"J Biol Chem."},{"issue":"5","key":"2526_CR25","doi-asserted-by":"crossref","first-page":"e1006350","DOI":"10.1371\/journal.ppat.1006350","volume":"13","author":"Z Ma","year":"2017","unstructured":"Ma Z, Hopcraft SE, Yang F, Petrucelli A, Guo H, Ting JP, et al. NLRX1 negatively modulates type I IFN to facilitate KSHV reactivation from latency. PLoS Pathog. 2017;13(5):e1006350.","journal-title":"PLoS Pathog"},{"issue":"4","key":"2526_CR26","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1128\/JVI.05376-11","volume":"86","author":"Y Ma","year":"2012","unstructured":"Ma Y, Jin H, Valyi-Nagy T, Cao Y, Yan Z, He B. Inhibition of TANK binding kinase 1 by herpes simplex virus 1 facilitates productive infection. J Virol. 2012;86(4):2188\u201396.","journal-title":"J Virol"},{"issue":"21","key":"2526_CR27","doi-asserted-by":"crossref","first-page":"14136","DOI":"10.1074\/jbc.M109.000414","volume":"284","author":"K Clark","year":"2009","unstructured":"Clark K, Plater L, Peggie M, Cohen P. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. J Biol Chem. 2009;284(21):14136\u201346.","journal-title":"J Biol Chem"},{"issue":"10","key":"2526_CR28","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1089\/hum.2012.080","volume":"23","author":"T Sutlu","year":"2012","unstructured":"Sutlu T, Nystrom S, Gilljam M, Stellan B, Applequist SE, Alici E. Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy. Hum Gene Ther. 2012;23(10):1090\u2013100.","journal-title":"Hum Gene Ther"},{"issue":"10","key":"2526_CR29","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/icb.2015.59","volume":"93","author":"MY Bilal","year":"2015","unstructured":"Bilal MY, Vacaflores A, Houtman JC. Optimization of methods for the genetic modification of human T cells. Immunol Cell Biol. 2015;93(10):896\u2013908.","journal-title":"Immunol Cell Biol"},{"issue":"3","key":"2526_CR30","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/sj.gt.3301378","volume":"8","author":"V Dardalhon","year":"2001","unstructured":"Dardalhon V, Herpers B, Noraz N, Pflumio F, Guetard D, Leveau C, et al. Lentivirus-mediated gene transfer in primary T cells is enhanced by a central DNA flap. Gene Ther. 2001;8(3):190\u20138.","journal-title":"Gene Ther"},{"issue":"4","key":"2526_CR31","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1128\/JVI.72.4.3161-3168.1998","volume":"72","author":"YD Korin","year":"1998","unstructured":"Korin YD, Zack JA. Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol. 1998;72(4):3161\u20138.","journal-title":"J Virol"},{"issue":"2","key":"2526_CR32","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1084\/jem.178.2.537","volume":"178","author":"M Lopez-Cabrera","year":"1993","unstructured":"Lopez-Cabrera M, Santis AG, Fernandez-Ruiz E, Blacher R, Esch F, Sanchez-Mateos P, et al. Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM\/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. J Exp Med. 1993;178(2):537\u201347.","journal-title":"J Exp Med"},{"issue":"7","key":"2526_CR33","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.4049\/jimmunol.149.7.2255","volume":"149","author":"C Cerdan","year":"1992","unstructured":"Cerdan C, Martin Y, Courcoul M, Brailly H, Mawas C, Birg F, et al. Prolonged IL-2 receptor alpha\/CD25 expression after T cell activation via the adhesion molecules CD2 and CD28. Demonstration of combined transcriptional and post-transcriptional regulation. J Immunol. 1992;149(7):2255\u201361.","journal-title":"J Immunol."},{"issue":"18","key":"2526_CR34","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1073\/pnas.1214441110","volume":"110","author":"D Finkelshtein","year":"2013","unstructured":"Finkelshtein D, Werman A, Novick D, Barak S, Rubinstein M. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A. 2013;110(18):7306\u201311.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"2526_CR35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cyto.a.22351","volume":"85","author":"A Larbi","year":"2014","unstructured":"Larbi A, Fulop T. From, \u201ctruly naive\u201d to \u201cexhausted senescent\u201d T cells: when markers predict functionality. Cytometry A. 2014;85(1):25\u201335.","journal-title":"Cytometry A."},{"issue":"1","key":"2526_CR36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2004-06-2482","volume":"105","author":"DJ Powell Jr","year":"2005","unstructured":"Powell DJ Jr, Dudley ME, Robbins PF, Rosenberg SA. Transition of late-stage effector T cells to CD27+\u2009CD28+\u2009tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood. 2005;105(1):241\u201350.","journal-title":"Blood"},{"issue":"9","key":"2526_CR37","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1084\/jem.20030916","volume":"198","author":"J Hendriks","year":"2003","unstructured":"Hendriks J, Xiao Y, Borst J. CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. J Exp Med. 2003;198(9):1369\u201380.","journal-title":"J Exp Med"},{"issue":"20","key":"2526_CR38","doi-asserted-by":"crossref","first-page":"19867","DOI":"10.1074\/jbc.M501367200","volume":"280","author":"RI Feldman","year":"2005","unstructured":"Feldman RI, Wu JM, Polokoff MA, Kochanny MJ, Dinter H, Zhu D, et al. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005;280(20):19867\u201374.","journal-title":"J Biol Chem"},{"issue":"4","key":"2526_CR39","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2567.2011.03412.x","volume":"132","author":"JP Huber","year":"2011","unstructured":"Huber JP, Farrar JD. Regulation of effector and memory T-cell functions by type I interferon. Immunology. 2011;132(4):466\u201374.","journal-title":"Immunology"},{"issue":"5","key":"2526_CR40","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.20050821","volume":"202","author":"GA Kolumam","year":"2005","unstructured":"Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med. 2005;202(5):637\u201350.","journal-title":"J Exp Med"},{"issue":"7","key":"2526_CR41","doi-asserted-by":"crossref","first-page":"e40865","DOI":"10.1371\/journal.pone.0040865","volume":"7","author":"SJ Keppler","year":"2012","unstructured":"Keppler SJ, Rosenits K, Koegl T, Vucikuja S, Aichele P. Signal 3 cytokines as modulators of primary immune responses during infections: the interplay of type I IFN and IL-12 in CD8 T cell responses. PLoS ONE. 2012;7(7):e40865.","journal-title":"PLoS ONE"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02526-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-020-02526-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02526-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T01:28:34Z","timestamp":1696728514000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-020-02526-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2526"],"URL":"https:\/\/doi.org\/10.1186\/s12967-020-02526-2","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,23]]},"assertion":[{"value":"22 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors reviewed the manuscript and agreed to proceed to publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The following patent US#9,856,497 relates to this work. Lei S. Qi is a co-founder and scientific advisor of Refuge Biotechnologies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"363"}}